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In the present study, the ability of Punica granatum ethanolic leaf extract (PGL) and Punica granatum 
ethanolic fruit extract (PGF) to induce mutagenicity or to modulate the genotoxic effects induced by the 
alkylating agent cyclophosphamide (CP) was evaluated. Swiss male mice were treated by gavage for 10 
days with PGL or PGF (12.5, 25, 50, and 75 mg/kg/day) prior to exposure to CP (i.p. 200 mg/kg), 24 h 
after the end of the treatment. Initial observations revealed that normal mice treated with both extracts 
(12.5, 25, 50, and 75 mg/kg/day) showed a similar micronucleated polychromatic erythrocyte (MNPCE) 
frequency to that of the control group. Investigation of the protective effect of PGL and PGF based on 
data analysis revealed that, irrespective of dose or extract, oral administration of PGL or PGF for 10 days 
prior to exposure had reduced, in a dose-dependent manner, the frequency of MNPCE induced by CP in 
all groups studied. Higher reductions were observed at PGF doses of 50 and 75 mg/kg. Taken together, 
these results demonstrate that mice treated with P. granatum showed an absence of mutagenic effects 
and dose-dependent protective effects against CP-induced oxidative DNA damage.
Uniterms: Punica granatum/mutagenic effects. Punica granatum/antimutagenic effects. Micronucleic. 
Genotoxicity. Cyclophosphamide.
No presente estudo investigamos o potencial do extrato etanólico das folhas da Punica granatum (PGFO) 
e do extrato etanólico dos frutos da Punica granatum (PGFR) de induzir mutagenicidade ou de proteger 
contra efeitos genotóxicos induzidos pela ciclofosfamida (CF). Camundongos machos Swiss foram 
tratados por 10 dias, via oral, com PGFO ou PGFR (12,5, 25, 50 e 75 mg/kg/dia), previamente a exposição 
à CF (i.p. 200 mg/kg) 24 horas após término do tratamento. Observamos que os animais tratados por 10 
dias com ambos os extratos (12,5, 25, 50 e 75 mg/kg/dia) demonstraram a frequência de micronúcleo 
policromático eritrocitário (MNPCE) similar ao grupo controle. Quando aos efeitos protetores dos extratos 
foram investigados, a análise dos dados revelou que, independentemente da dose ou do extrato usado, a 
administração oral por 10 dias, previamente à exposição, reduziu, de forma dose-dependente, a frequência 
de MNPCE induzidos pela CF, em todos os grupos estudados. As maiores reduções foram observadas 
com PGFR nas doses de 50 e 75 mg/kg. Em conjunto, sob as condições testadas, camundongos tratados 
com P. granatum demonstraram ausência de efeitos mutagênicos e, de forma dose-dependente, efeitos 
protetores contra os danos oxidativos do DNA induzidos pela CF. 
Unitermos: Punica granatum/efeitos mutagênicos. Punica granatum/efeitos antimutagênicos. 
Micronúcleo. Genotoxicidade. Ciclofosfamida.
INTRODUCTION
Punica granatum Linn., a Punicaceae, commonly 
known as pomegranate, has a vast ethnomedical history 
and represents a phytochemical reservoir of heuristic me-
dicinal value (Lansky and Newman, 2007). The plant as 
a whole and especially its flowers, have been extensively 
used in the ancient Ayurvedic health care system (Sivara-
jan and Balachandran, 1994).
In fact, studies on P. granatum phytochemistry and 
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pharmacological actions suggest a wide range of poten-
tial clinical applications. Antitumour (Afaq et al., 2005; 
Lansky and Newman, 2007), antibacterial (Prashanth et 
al., 2001; Braga et al., 2005; Menezes et al., 2006; Aqil, 
Ahmad, 2007), antidiarrhoeal (Das et al., 1999; Mathabe 
et al., 2006), antifungal (Dutta et al., 1998; Vasconcelos et 
al., 2003; Vasconcelos et al., 2006), antiulcer (Gharzouli 
et al., 1999), and antioxidant pharmacological properties 
have been reported for various extracts/constituents of 
different parts of this plant species.
Recently, the antioxidant activity of P. granatum 
associated with its phytochemicals, such as, polyphenols, 
flavonoids, and anthocyanidins has gained importance 
(Faria et al., 2007; Guo et al., 2007; Kulkarni et al., 
2007; Mirdehghan et al., 2007; Reddy et al., 2007; Rout, 
Banerjee, 2007; Sestili et al., 2007; Zaid et al., 2007). 
In this regard, Negi et al. (2003) demonstrated that the 
in vitro antioxidant ability of the pomegranate fruit, rich 
in polyphenols and anthocyanidins, was higher than that 
found in green tea, also considered a powerful antioxidant. 
Several extracts/constituents of P. granatum have been 
found to prevent low-density lipoprotein oxidation and 
hence are antiarthrogenic (Aviram et al., 2002; Wang et al., 
2004), modulating the expression of oxidation-sensitive 
genes in vitro and in hypercholesterolemic mice (De Nigris 
et al., 2005), as well as inhibiting the nuclear factor κβ, 
which is activated by reactive oxygen species (ROS) (Afaq 
et al., 2005). Moreover, Guo et al. (2007) demonstrated 
in vitro, a powerful DNA damage prevention ability of P. 
granatum. Although extracts from many parts of this plant, 
including its fruit, seeds, and peel, have been reported 
to exhibit strong antioxidant activity in vitro, important 
confirmation and characterization of these effects using 
biological systems in vivo were lacking. Cerda et al. (2004, 
2006) suggested that the clinical antioxidative efficacy of 
pomegranate could be impaired by the poor bioavailability 
found in its active compounds.
P. granatum is generally considered safe due to the 
fact that it is widely consumed by numerous populations 
in many different countries. However, toxic effects have 
been ascribed to the consumption of this plant, including 
acute gastric inflammation, congestion of internal organs 
with elevated creatinine in vivo (Vidal et al., 2003), and 
even death, as well as, allergic reactions (Gaig et al., 1999; 
Hegde et al., 2002; Igea et al., 1991; Lansky, Newman, 
2007).
Genetic toxicology tests are assays designed to de-
tect direct or indirect genetic damage induced by chemical 
compounds. Fixation of DNA damage can result in gene 
mutations, loss of heterozygosity, chromosome loss or 
gain, and chromosome aberrations. These events may play 
an important role in many malignancies. Thus, identifying 
genotoxic/mutagenic effects is important for the risk/be-
nefit assessment of substances, in particular those which 
are part of the dietary habits of any populations (Doppa-
lapudi et al., 2007). The in vivo mouse bone marrow mi-
cronucleus (MN) assay is currently recommended by the 
International Conference on Harmonization (ICH, 1997), 
the Food and Drug Administration, and other regulatory 
agencies (Cimino, 2006) to investigate the genotoxic/
chemopreventive potential of new agents. In addition, a 
direct connection between increase in MN frequency and 
development of carcinogenesis has been documented in 
the literature (Olaharski et al., 2006). 
The present work was designed to further investi-
gate the effects of P. granatum on biological systems and 
aimed to study the ability of both its ethanolic leaf extract 
(PGL) and ethanolic fruit extract (PGF) to induce muta-
genicity or modulate the genotoxic effects induced by the 
alkylating agent cyclophosphamide (CP) in mice, using 
the micronucleus test.
MATERIAL AND METHODS
Mice treatment
The experiments were carried out on adult male 
Swiss mice (8-12 week) obtained from Indústria Química 
do Estado de Goiás (IQUEGO). All mice weighed between 
28 g and 30 g and were kept under constant environmen-
tal conditions with a 12:12 light-dark cycle. The animals 
were fed standard granulated chow and had access to 
drinking water ad libitum. Animal experiments were 
done in accordance with Institutional Protocols of Animal 
Care. The mice groups (n=5) received PGL or PGF daily 
doses of 12.5; 25; 50 or 75 mg/kg (0.2 mL/mouse), for 10 
consecutive days by gavage, prior to exposition. For the 
antimutagenic assay, mice were exposed to cyclophospha-
mide, (CP) (Genuxal®, Baxter Oncology, Lot# 7K585B, 
Expiration date 11/2010) i.p., (200 mg/kg) 24 h after the 
end of the treatment, administrated as a single dose diluted 
in physiological saline. Each experiment included parallel 
control groups of normal and exposed mice treated with an 
equivalent volume (0.2 mL/animal) of the vehicle (n=5). 
The micronuclei frequency quantification was performed 
24 h after exposure to cyclophosphamide. 
Extract preparation
Plant material from P. granatum, leaves and fruits, 
was collected in September 2005 in Goiânia, Goiás State, 
Brazil. The fruits or leaves were dried and ground to a po-
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wder and both, PGL and PGF, were prepared according to 
guidelines of the Brazilian Pharmacopoeia. After filtration, 
both PGL and PGE were rotaevaporated to dryness under 
low pressure and temperature. The extracts obtained were 
kept at 4 °C.
Micronucleus test
The mutagenicity and antimutagenicity of PGL 
and PGF were evaluated using the micronucleus test by 
scoring 1000 bone marrow cells for each of the 5 animals 
per treatment group, as described by MacGregor et al. 
(1987). To detect possible cytotoxic effects, the proportion 
of polychromatic erythrocytes (PCE) and normochroma-
tic erythrocytes (NCE) in 1000 erythrocytes/animal was 
calculated. We stained the cells with Leishman, coded the 
slides, and scored in a blind test using a light microscope 
(1000 x magnification). The frequency of micronuclea-
ted polychromatic erythrocytes (MNPCE) in individual 
mice was used as the experimental unit, with variability 
(standard deviation) based on differences among animals 
within the same group.
Statistical analysis
The data from the micronucleus assay were sta-
tistically analyzed using Student’s t-test, comparing the 
treated groups with controls (Pereira, 1991). The signi-
ficance level considered was P<0.05. The percentage of 
reduction in the frequency of CP-induced DNA damage 
was calculated according to Manoharan and Banerjee 
(1985), by the following formula: % reduction = ((mean 
frequency of damage in A - mean frequency of damage in 
B)/(mean frequency of damage in A - mean frequency of 
damage in C)) x 100.
Where, A = positive control group treated with CP; 
B = group treated with the PGL or PGF + CP; C = negative 
control group.
RESULTS
The frequency of MNPCE in bone marrow cells 
of mice orally treated with different doses of PGL and 
PGF (12.5, 25, 50, 75 mg/kg) are shown in Figure 1. Oral 
treatment with PGL and PGF for 10 days did not induce 
any mutagenic effects in mouse bone marrow cells, i.e., 
no statistically significant difference in the frequency of 
MNPCE or the ratio of PCE to NCE between the nega-
tive control and the groups treated with PGL and PGF 
was detected. In fact, a tendency toward a decrease in 
normal MNPCE frequency in control mice at the dose of 
75 mg/kg of PGF was observed.
The effects of the prophylactic treatment with PGL 
and PGF on the frequencies of MNPCE in mice bone mar-
row 24 h after exposure to CP, an indirect alkylant agent, 
are shown in Figure 2. Examination of the antimutageni-
city profile of the extracts revealed significant decrease 
(P < 0.05), in a dose-dependent manner, in the frequency 
of CP-induced MNPCE in all groups. The highest doses of 
PGF were found to be more effective against CP-induced 
DNA damage. Figure 3 shows the percentage reduction 
in the frequency of MNPCE in mice pre-treated with PGL 
FIGURE 1 - Effects of prophylactic oral treatment with Punica granatum ethanolic leaf extract - PGL (A) and ethanolic fruit extract 
- PGF (B) (12.5, 25, 50, 75 mg/kg/day) for 10 days, on the frequency of micronucleated polychromatic erythrocytes (MNPCE) 
in mice (n = 5).
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and PGF. Daily PGL doses of 12.5, 25, 50, or 75 mg/kg 
reduced the frequency of MN by 35, 56, 61 and 60%, 
whereas treatment with 12.5, 25, 50, or 75 mg/kg of PGF 
led to 45, 69, 80 and 80% reduction, respectively.
DISCUSSION
The concept that environmental chemical exposure 
could induce DNA damage has led to the introduction 
of requirements for testing mutagenic properties of new 
and/or frequently consumed substances, especially food. 
However, it has been documented in the literature that 
antioxidant intake can reduce cancer risk and may also 
mitigate the effects of oxidative DNA damage (Watters 
et al., 2007). In the present study, we evaluated the mu-
tagenic and anti-mutagenic potential of PGL and PGF in 
mouse bone marrow cells. Our first observation was that 
normal mice orally treated for 10 days with both extracts 
showed micronuclei frequency similar to that found in the 
control group. When the protective effect of PGL and PGF 
were investigated in mouse bone marrow cells, the data 
analysis revealed that, irrespective of dose or extract, the 
treatments reduced the frequency of MNPCE induced by 
CP exposure. The oral administration of 12.5, 25, 50, and 
75 mg/kg/day of PGL or PGF for 10 days prior to CP expo-
sure reduced, in a dose-dependent manner, the frequency 
of MNPCE induced by CP in all groups studied. Higher 
reductions were observed at higher PGF doses (50 and 
75 mg/kg). These results are in accordance with the findin-
gs of Guo et al. (2007), which demonstrated in vitro that 
besides scavenging free radicals and ROS, P. granatum 
also prevents DNA damage. Therefore, our results confirm 
and extend our knowledge on the ability of P. granatum 
to protect DNA, showing that both PGL and PGF prevent 
chromosome damage after CP exposure in mice.
In recent years, attention has been focused on the 
antioxidant properties elicited by plants or food against 
ROS, lipid peroxidation, protein damage, and DNA strand 
breaking. Several plants can positively modulate biologi-
cal systems against damaging effects produced by active 
oxygen species by several means, including free radical 
scavengers and enzymes such as superoxide dismutase 
(SOD) and catalase (CAT) (Srinivasan et al., 2007). 
The antioxidant activities of P. granatum are as-
sociated with different bioactive components, mainly 
polyphenols, ellagitannins, condensed tannins, and an-
thocyanins (Kulkarni et al., 2004; Li et al., 2006; Negi 
et al., 2003; Noda et al., 2002). In this regard, West et 
al. (2007) showed that polyphenols present in this plant 
protect neonatal mouse brain against hypoxic-ischemic 
injury. Other examples of beneficial antioxidant activity 
effects of P. granatum include inhibition of UVB-mediated 
oxidative stress in immortalized HaCaT keratinocyte cells 
(Zaid et al., 2007), augmentation of the human immune 
system’s antioxidant and thus antimalarial and antimi-
crobial capacities in vitro (Reddy et al., 2007), decrease 
in the expression of the vascular inflammation markers 
thrombospondin and cytokine TGFbeta1, along with an 
increase in plasma nitrate and nitrite levels and endothelial 
NO synthase expression in obese Zucker rats (De Nigris 
et al., 2007). Moreover, Kaur et al. (2006) demonstrated 
FIGURE 2 - Effects of prophylactic oral treatment with Punica 
granatum ethanolic leaf extract - PGL and the ethanolic fruit 
extract - PGF (12.5; 25; 50 or 75mg/kg/day) for 10 days on 
the frequency of micronucleated polychromatic erythrocytes 
(MNPCE) in mice (n = 5) exposed to cyclophosphamide (CP). 
*P < 0.05 when compared to negative control; #P < 0.05 when 
compared to positive control.
FIGURE 3 - Percentage micronucleated polychromatic 
erythrocyte (MNPCE) reduction in mice (n = 5) orally pre-
treated with Punica granatum ethanolic leaf extract - PGL or 
ethanolic fruit extract - PGF (12.5, 25, 50, 75 mg/kg/day) for 10 
days and exposed to cyclophosphamide (CP).
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that P. granatum extract afforded up to 60% protection 
against hepatic lipid peroxidation due to the maintenance 
of the glutathione levels and activities of CAT, glutathione 
peroxidase, glutathione reductase, and glutathione-S-
transferase.
Although the biochemical mechanisms underlying 
PGL and PGF activities are not yet clear, our results de-
monstrated in vivo that P. granatum has a preventive effect 
against chromosome fragmentation and/or damage to the 
mitotic apparatus, probably due to its free radical scaven-
ging capability. Taken together, under the conditions tested 
herein, mice treated with P. granatum showed an absence 
of mutagenic effects and dose-dependent protective effects 
against CP induced oxidative DNA damage. 
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